AlphaCentric Advisors’s Phathom Pharmaceuticals PHAT Stock Holding History

AlphaCentric Advisors’s Portfolio PHAT Stock Details PHAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-160,000	Closed	-$1.66M	–	274
2023 Q3	$1.66M	Buy	160,000 +30,000	+23%	+$412K	0.94%	35
2023 Q2	$1.86M	Buy	+130,000	New	+$1.5M	1.03%	30

Other funds holding PHAT

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

TPC

Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return

MVM

Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

AlphaCentric Advisors's PHAT Position: Q4 2023 in Review

AlphaCentric Advisors sold out of Phathom Pharmaceuticals (PHAT) in Q4 2023, closing a stake of 160,000 shares — an estimated $1.66M sold.

AlphaCentric Advisors first reported a position in PHAT in Q2 2023 and held it in 2 quarters. The position peaked at $1.86M in Q2 2023. 117 funds tracked by Wall St. Rank hold PHAT as of Q4 2023.

AlphaCentric Advisors reported no remaining Phathom Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
AlphaCentric Advisors sold 160,000 Phathom Pharmaceuticals shares in Q4 2023, an estimated $1.66M.
AlphaCentric Advisors first reported a position in Phathom Pharmaceuticals in Q2 2023 and held it in 2 quarters.
AlphaCentric Advisors's Phathom Pharmaceuticals position peaked at $1.86M in Q2 2023.
117 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q4 2023.

Based on AlphaCentric Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.